» Articles » PMID: 23017648

Colonic Inflammation in Parkinson's Disease

Overview
Journal Neurobiol Dis
Specialty Neurology
Date 2012 Sep 29
PMID 23017648
Citations 285
Authors
Affiliations
Soon will be listed here.
Abstract

Lewy pathology affects the gastrointestinal tract in Parkinson's disease (PD) and data from recent genetic studies suggest a link between PD and gut inflammation. We therefore undertook the present survey to investigate whether gastrointestinal inflammation occurs in PD patients. Nineteen PD patients and 14 age-matched healthy controls were included. For each PD patients, neurological and gastrointestinal symptoms were assessed using the Unified Parkinson's Disease Rating Scale part III and the Rome III questionnaire, respectively and cumulative lifetime dose of L-dopa was calculated. Four biopsies were taken from the ascending colon during the course of a total colonoscopy in controls and PD patients. The mRNA expression levels of pro-inflammatory cytokines (tumor necrosis factor alpha, interferon gamma, interleukin-6 and interleukin-1 beta) and glial marker (Glial fibrillary acidic protein, Sox-10 and S100-beta) were analyzed using real-time PCR in two-pooled biopsies. Immunohistochemical analysis was performed on the two remaining biopsies using antibodies against phosphorylated alpha-synuclein to detect Lewy pathology. The mRNA expression levels of pro-inflammatory cytokines as well as of two glial markers (Glial fibrillary acidic protein and Sox-10) were significantly elevated in the ascending colon of PD patients with respect to controls. The levels of tumor necrosis factor alpha, interferon gamma, interleukin-6, interleukin-1 beta and Sox-10 were negatively correlated with disease duration. By contrast, no correlations were found between the levels of pro-inflammatory cytokines or glial markers and disease severity, gastrointestinal symptoms or cumulative lifetime dose of L-dopa. There was no significant difference in the expression of pro-inflammatory cytokines or glial marker between patients with and without enteric Lewy pathology. Our findings provide evidence that enteric inflammation occurs in PD and further reinforce the role of peripheral inflammation in the initiation and/or the progression of the disease.

Citing Articles

The interrelationship between intestinal immune cells and enteric α-synuclein in the progression of Parkinson's disease.

Cheng Y, Chiang H Neurol Sci. 2025; .

PMID: 40085320 DOI: 10.1007/s10072-025-08114-w.


SVHRSP protects against rotenone-induced neurodegeneration in mice by inhibiting TLR4/NF-κB-mediated neuroinflammation via gut microbiota.

Chen M, Zhang Y, Hou L, Zhao Z, Tang P, Sun Q NPJ Parkinsons Dis. 2025; 11(1):43.

PMID: 40050294 PMC: 11885645. DOI: 10.1038/s41531-025-00892-6.


Chronic DSS-Induced Colitis Exacerbates Parkinson's Disease Phenotype and Its Pathological Features Following Intragastric Rotenone Exposure.

Sharma N, Sharma M, Thakkar D, Kumar H, Smetanova S, Buresova L ACS Pharmacol Transl Sci. 2025; 8(2):346-367.

PMID: 39974653 PMC: 11833723. DOI: 10.1021/acsptsci.4c00286.


A Novel Rat Model for Inflammatory Gut-Brain Interactions in Parkinson's Disease.

Kendall G, Underwood C, Parr-Brownlie L Eur J Neurosci. 2025; 61(2):e16667.

PMID: 39844519 PMC: 11754928. DOI: 10.1111/ejn.16667.


TNBS colitis induces architectural changes and alpha-synuclein overexpression in mouse distal colon: A morphological study.

Casini A, Vivacqua G, Ceci L, Leone S, Vaccaro R, Tagliafierro M Cell Tissue Res. 2024; 399(2):247-265.

PMID: 39656240 PMC: 11787265. DOI: 10.1007/s00441-024-03932-4.